July 2, 2019 07:26 AM EDTUpdated July 3, 06:53 AM
R&D
FDA+

Watch out Ab­b­Vie: Gilead is fast on your heels at the FDA with ri­val JAK in­hibitor fil­go­tinib

Amber Tong

Mov­ing fast with what it be­lieves is a block­buster fa­vorite in a crowd­ed mar­ket, Gilead has con­fi­dent­ly plot­ted an NDA fil­ing for fil­go­tinib by the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times